Latest Biotech News

Tessera Therapeutics plans to lay off 90 employees even as it prepares to initiate its first clinical study, according to internal documents. The move follows an organizational reshaping as the...

GSK and Helix struck a multi‑year collaboration giving GSK access to curated clinico‑genomic cohorts in Helix’s GenoSphere database to support precision‑medicine drug R&D. The arrangement includes...

Eli Lilly agreed to acquire Ventyx Biosciences for about $1.2 billion, adding clinical-stage oral NLRP3 inhibitors to its pipeline. The deal consolidates Lilly’s push into inflammation and...

GSK and development partner Ionis announced positive topline results from two pivotal Phase 3 trials of bepirovirsen, an antisense oligonucleotide aimed at inducing functional cure in chronic...

Alumis released top-line results from two Phase 3 trials showing envudeucitinib (an oral TYK2 inhibitor) met co-primary and key secondary endpoints in moderate-to-severe plaque psoriasis. The...

Amgen announced multiple Europe-focused oncology deals that together could be worth roughly $1.46 billion, including the acquisition of Dark Blue Therapeutics and a license pact with Disco...

Sanofi agreed a multi-year collaboration with AI-driven Earendil Labs to discover and develop bispecific antibodies for autoimmune and inflammatory diseases, a partnership valued at up to $2.56...

Arrowhead Pharmaceuticals published early clinical signals showing its RNAi candidates reduced visceral and liver fat when dosed in combination with Lilly’s tirzepatide (Zepbound). The company...

The U.S. Department of Health and Human Services and CDC revised the federal pediatric vaccine schedule, moving recommendations for six diseases from universal guidance to risk-based or shared...

A Nature paper described a gene therapy approach that targets cortical pain circuits to reproduce opioid-like analgesia without addiction in mouse models. Researchers used circuit-specific...

A study in Nature Biomedical Engineering reported that engineered outer membrane vesicles (OMVs) can boost CAR‑T cell activity against solid tumors. Researchers modified bacterial OMVs to deliver...

A preclinical study published in Nature Communications demonstrated boron neutron capture therapy (BNCT) can preserve immune cell integrity while triggering robust anti-tumor immune responses in...

Eli Lilly agreed to acquire Ventyx Biosciences for roughly $1.2 billion, taking control of a clinical-stage oral NLRP3 inhibitor program that targets inflammatory pathways implicated across...

Alumis reported positive Phase III results for envudeucitinib, a selective oral TYK2 inhibitor, meeting co‑primary endpoints in two pivotal trials for moderate-to-severe plaque psoriasis. The...

GSK and development partner Ionis announced positive topline results from two pivotal Phase III studies of bepirovirsen, an antisense oligonucleotide for chronic hepatitis B that met its main...

Amgen struck deals to bolster its oncology pipeline by acquiring Dark Blue Therapeutics and inking related European partnerships that add targeted protein degradation programs and novel cancer...

Sanofi signed a collaboration with Earendil Labs worth up to $2.56 billion to discover and develop bispecific antibodies for autoimmune and inflammatory diseases using Earendil’s AI-driven...

Eli Lilly expanded its obesity playbook with a licensing agreement with Nimbus Therapeutics worth up to $1.3 billion to develop an oral obesity therapy, while early clinical data from Arrowhead...

U.S. health officials revised the federal childhood immunization schedule, narrowing routine recommendations and moving several vaccines to risk‑based or shared‑decision categories. The Centers...

OpenAI launched ChatGPT Health, a dedicated offering for health-related conversations designed to help users navigate personal health information rather than provide diagnoses. The company invited...